Publications by authors named "Lanqiu Liu"
J Hematol Oncol
October 2024
Article Synopsis
- * China's dual-track regulatory framework has led to it becoming the second largest nation for cell therapy clinical trials, with a significant focus on hematologic malignancies despite a high demand for treatments for solid tumors.
- * The study reveals that over 90% of cell therapy trials in China are investigator-initiated, highlighting the need for stricter regulations and guidelines to minimize redundant research and promote value-driven product development.
